CDSCO Panel Approves Updated Package Insert for Takeda's Vedolizumab

Published On 2025-11-05 10:46 GMT | Update On 2025-11-05 10:46 GMT

New Delhi: In a key regulatory development, the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has approved the updated package insert for Vedolizumab 300 mg and 108 mg powder for concentrate for solution for infusion, marketed by Takeda Biopharmaceuticals India.

The company had presented its proposal seeking approval for amendments in Section 4.6 (Use in Special Population) of the drug’s package insert, aligning it with the Company Core Data Sheet (CCDS) Version 9.0

Vedolizumab is an integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults.

Also Read: Intas Pharmaceutical Gets CDSCO Panel Nod to study Vedolizumab Powder for Concentrate for Solution for Infusion

Vedolizumab was developed by Takeda and approved by the FDA under the brand name ENTYVIO for the maintenance therapy of moderately to severely active Ulcerative Colitis and Crohn’s Disease in April and September 2023, respectively.

Vedolizumab is a humanized monoclonal antibody that specifically binds to the α4β7 integrin and blocks the interaction of α4β7 integrin with MAdCAM-1. Vedolizumab does not bind to or inhibit the function of the α4β1 and αEβ7 integrins and does not antagonize the interaction of α4 integrins with vascular cell adhesion molecule-1 (VCAM-1).

After detailed deliberation, the committee recommended for approval of updated package insert for the proposed changes.

Also Read: Intas Pharmaceuticals Gets CDSCO Panel Nod to Study Vedolizumab for Ulcerative Colitis

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Susmita Roy

Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of Pharmacy in West Bengal. She has been part of Medical Dialogues since March 2021.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

CDSCO Panel Approves Updated Package Insert for Takeda's Vedolizumab

Similar News

CDSCO Panel Approves Updated Package Insert for Johnson and Johnson's Stelara

Ziller Medical Denied Manufacturing Nod for Cervical Cerclage Pessary Over Inadequate Safety Data

CDSCO Panel Asks Shilpa Biologicals to Revise Phase III Protocol for Recombinant Human Serum Albumin Study

Low-Risk Medical Device Makers Get Clarity: CDSCO Publishes Class A Risk Classification List under MDR 2017

AstraZeneca Gets SEC Nod to Update Lokelma Prescribing Information for Hyperkalemia Treatment

Akums Wins 20-Year Patent for Dual Release PPI, Promises Long-Lasting GERD Relief

MSN Labs Secures SEC Nod for Phase III Trial of Vibegron 75 mg, Excluding Refractory OAB Patients